US Psychiatric Drug "Price-Gouging:" Report

16 July 1998

The US prices of eight commonly-used antidepressants and schizophreniadrugs are, on average, double the rates charged in European countries, says a study conducted by the US consumer advocacy group Public Citizen into the products' prices in 17 countries.

The prices of all eight drugs were higher in the USA than anywhere else, it says. In particular: - Novartis' Clozaril (clozapine) costs $51.94 for a 30-day supply in Spain, and $317.03 in the USA. It costs $271.08 in Canada and $294.93 in the UK; - Janssen's Risperdal (risperidone) costs $123.99 for a 30-day supply in France, and $248.86 in the USA; and - Eli Lilly's Prozac (fluoxetine) sells for $25.93 in Spain and $72.16 in the USA.

The report said drug firms do not have to make such extraordinarily high profits, despite the fact that they invest heavily in R&D. US sales of $3.3 billion are estimated for the five antidepressants, while for the three antipsychotics the estimate is $1.1 billion. US companies are making average profits of over 40%, it said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight